Why BioVie Inc.’s Phase 2 bezisterim data could shift the Parkinson’s disease treatment paradigm
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Pharma & Biotech